DRI Healthcare Trust - CEO, Behzad Khosrowshahi
CEO, Behzad Khosrowshahi
Source: DRI Capital
Market Herald logo

Subscribe

Be the first with the news that moves the market
  •  DRI Healthcare Trust (DHT.UN) receives FDA approval for VONJO
  • VONJO is a drug candidate to treat adults with intermediate or high-risk primary or secondary myelofibrosis
  • The approval allowed completion of a transaction with CTI BioPharma Corp. for a tiered royalty on VONJO for US$60 million
  • The completion of the royalty transaction is expected to happen by Friday
  •  DRI Healthcare Trust (DHT.UN) is up 10.74 per cent trading at $6.70 per share as of 11:49 a.m. EST

DRI Healthcare Trust (DHT UN) has received FDA approval for VONJO, a drug candidate to treat adults with primary or secondary myelofibrosis.

Myelofibrosis is a bone marrow cancer that results in the formation of fibrous scar tissue and can lead to anemia, weakness, fatigue and an enlarged spleen or liver.

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, stated,

“We are very pleased that the FDA has approved VONJO, a groundbreaking drug that addresses a high unmet medical need, offering a meaningful new treatment option for adults with myelofibrosis with thrombocytopenia, a patient population for whom therapies do not currently exist.”

The approval resulted in the completion of a transaction with CTI BioPharma Corp. for a tiered royalty on VONJO for US$60 million, as announced in August.

The transaction entitles DRI to receive royalties on the net sales of VONJO in the United States equal to 9.6 per cent of the first US$125 million of annual net sales, 4.5 per cent between US$125 million and US$175 million, and 0.5 per cent between US$175 million and US$400 million. DRI will have no entitlement above US$400 million of the annual net sales.

CTI is entitled to an additional US$25 million if VONJO sales exceed certain thresholds before Q3 2023.

The royalty transaction is expected to be completed by Friday, March 4th.

“The addition of the VONJO royalty provides an attractive, growing cash flow profile and extends our overall portfolio duration,” said Khosrowshahi.

DRI Healthcare Trust (DHT.UN) is up 10.74 per cent trading at $6.70 per share as of 11:49 a.m. EST.

More From The Market Herald

" Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Satellos Bioscience (MSCL) has filed a patent application with the US Patent and Trademark Office.

" NervGen Pharma (TSXV:NGEN) announces US$15M private placement

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.

" Feeding our plant-based future

One of the fastest-growing segments today is the plant-based industry, as the push towards cleaner lifestyles, eating habits, and sustainable living choices fuel

" Salona Global (TSXV:SGMD) expands product distribution

Salona Global (SGMD) has signed an agreement to distribute the Hyperice suite of products and delivered 600 units of its newly launched Mio-Guard.